Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for breast cancer and other diseases. Its lead product candidate is (Z)-endoxifen, an active metabolite of Tamoxifen, being studied in women with breast cancer and for Duchenne muscular dystrophy (DMD). The company is pursuing FDA approval and has applied for Rare Pediatric Disease Priority Review Voucher and orphan-drug exclusivity designations for DMD.
expected 2026-12-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001193125-26-124396 | EDGAR | 59K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044099 | EDGAR | 54K words |
| 2024-04-01 | 2023-12-31 | 0000950170-24-039306 | EDGAR | 60K words |
| 2023-03-22 | 2022-12-31 | 0001437749-23-007531 | EDGAR | 54K words |
| 2022-02-28 | 2021-12-31 | 0001437749-22-004614 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001437749-21-007756 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001437749-20-006155 | EDGAR | — |
| 2019-03-28 | 2018-12-31 | 0001437749-19-005927 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001615774-18-001693 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001615774-17-001088 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001193125-26-339257 | EDGAR | 36K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-276160 | EDGAR | 35K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106947 | EDGAR | 34K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069827 | EDGAR | 33K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124668 | EDGAR | 34K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095102 | EDGAR | 32K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058244 | EDGAR | 31K words |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031424 | EDGAR | 38K words |
| 2023-08-14 | 2023-06-30 | 0001437749-23-023426 | EDGAR | 37K words |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014366 | EDGAR | 34K words |
| 2022-11-07 | 2022-09-30 | 0001437749-22-026178 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001437749-22-019359 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-18 | 0001193125-26-395694 | EDGAR | 4K words |
| 2026-08-07 | 0001193125-26-339292 | EDGAR | 4K words |
| 2026-03-25 | 0001193125-26-124393 | EDGAR | 3K words |
| 2026-02-20 | 0001193125-26-061412 | EDGAR | 22K words |
| 2026-02-17 | 0001193125-26-054797 | EDGAR | 1K words |
| 2026-02-11 | 0001193125-26-045628 | EDGAR | 2K words |
| 2026-01-26 | 0001193125-26-021727 | EDGAR | 1K words |
| 2026-01-09 | 0001193125-26-008314 | EDGAR | 1K words |
| 2026-01-06 | 0001193125-26-003506 | EDGAR | 1K words |
| 2025-12-04 | 0001193125-25-307516 | EDGAR | 1K words |
304 total filings indexed. 272 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001488039 |
| Ticker | ATOS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.atossatherapeutics.com |
| Listed | 2012-11-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ATOS (~200 tokens, structured JSON with cryptographic provenance)